CBio Limited is an Australian company with a global focus. With a vision to improve patient lives, CBio is focused on developing new generation products for the treatment of autoimmune and inflammatory diseases.

CBio was established in 2000 to develop and commercialise treatments for autoimmune diseases. In 2001, extended preclinical studies at the University of Queensland concluded that a heat shock protein identified as chaperonin 10 played a key role in down-regulating the innate immune response in patients during pregnancy. Further research suggested that chaperonin 10 appeared to intercede at a very early stage of the inflammatory process to prevent the over-expression of pro-inflammatory cytokines. Based on this research, CBio acquired a worldwide exclusive licence for the chaperonin 10 intellectual property, and now has an extensive IP portfolio surrounding the technology.

The registered trademark for CBio’s patented lead molecule is XToll®.

CBio has evolved from a research-based operation into an early-stage drug development organisation. This strategic transformation is the result of the recruitment and appointment of board members, management and staff with drug development expertise and capabilities.

The strategy of the Company is to complete the development projects that will add the greatest value to its primary asset, XToll®.